GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verseon Corp (GREY:VERS) » Definitions » Loans Receivable

Verseon (Verseon) Loans Receivable : $0.00 Mil (As of Jun. 2019)


View and export this data going back to 2016. Start your Free Trial

What is Verseon Loans Receivable?

Verseon's Loans Receivable for the quarter that ended in Jun. 2019 was $0.00 Mil.


Verseon Loans Receivable Historical Data

The historical data trend for Verseon's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verseon Loans Receivable Chart

Verseon Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Loans Receivable
Get a 7-Day Free Trial - - - - -

Verseon Semi-Annual Data
Dec11 Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Verseon Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Verseon Loans Receivable Related Terms

Thank you for viewing the detailed overview of Verseon's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Verseon (Verseon) Business Description

Traded in Other Exchanges
N/A
Address
47071 Bayside Parkway, Fremont, CA, USA, 94538
Verseon Corp is a part of the healthcare sector in the United States. It is a technology-based pharmaceutical company with a computer-driven drug discovery platform. The company designs novel drug candidates that are unlikely to be found using conventional methods. It is also engaged in drug discovery programs such as the diabetic macular edema product candidates, which treat the diseases by controlled disruption of the kallikrein kinin cascade.

Verseon (Verseon) Headlines